Effect of BAFF/APRIL mRNA expression induced by glucocorticoid and bortezomib in multiple myeloma cells in vitro.
- Author:
Ling-Shu LI
1
;
Jian-Kai SHEN
;
Guang-Sen ZHANG
Author Information
1. Department of Hematology, Central South University Xiangya Second Hospital, Hunan Province, China.
- Publication Type:Journal Article
- MeSH:
B-Cell Activating Factor;
genetics;
metabolism;
Boronic Acids;
pharmacology;
Bortezomib;
Cell Line, Tumor;
Gene Expression Regulation, Neoplastic;
drug effects;
Glucocorticoids;
pharmacology;
Humans;
Multiple Myeloma;
metabolism;
Pyrazines;
pharmacology;
RNA, Messenger;
genetics;
Tumor Necrosis Factor Ligand Superfamily Member 13;
genetics;
metabolism
- From:
Journal of Experimental Hematology
2011;19(6):1419-1423
- CountryChina
- Language:Chinese
-
Abstract:
The study was purposed to detect BAFF/APRIL gene expression changes in bone marrow mononuclear cells (BMMNC) and myeloma cell line U266 after interference with glucocorticoid and bortezomib. After separation of BMMNC from 7 patients with multiple myeloma, BAFF/APRIL mRNA expression in BMMNC and U266 cell line was detected by real-time PCR after treated with dexamethasone 100, 200 µg/ml, methylprednisolone 100, 200 µg/ml, bortezomib 0.1 µg/ml alone and dexamethasone or methylprednisolone combined with bortezomib respectively for 48 hours. The results showed that U266 cells and BMMNC of untreated MM patients highly expressed BAFF/APRIL genes. When dexamethasone, methylprednisolone or bortezomib was added to U266 cells or BMMNC alone, BAFF/APRIL gene expression decreased as compared with the blank control (p < 0.01). The inhibiting effect of bortezomib to BAFF/APRIL expression was obviously strong(p < 0.05). When dexamethasone or methylprednisolone combined with bortezomib, the BAFF/APRIL gene expression further decreased compared with dexamethasone or methylprednisolone alone (p < 0.01). As compared with the group of methylprednisolone combined with bortezomib, BAFF/APRIL gene expression decreased in dexamethasone combined with bortezomib with a statistically significant difference (p < 0.05). It is concluded that the expression of BAFF/APRIL gene is down-regulated after bing treated with glucocorticoids and bortezomib, which suggests that besides the glucocorticoid receptor and proteasomes targets, BAFF/APRIL and their receptor sites may be new targets of glucocorticoids and bortezomib.
